Cellevate to pre-launch first nanofiber microcarriers for boosting viral vector production in gene therapy applications at CPHI Milan

LUND, Sweden - Cellevate, an innovative biotech company developing next-generation cell culture systems to revolutionize biomanufacturing, is ready to pre-launch the world’s 1^st nanofiber microcarrier for gene therapy at CPHI Milan, October 8-10, 2024.

By providing up to 60 times more surface area for cell growth than conventional systems, Cellevat3d^® nanofiber microcarriers increase yield and productivity in upstream bioprocessing of gene therapy applications. Engineered for stirred tank bioreactors, Cellevat3d^® nanofiber microcarriers support a wide range of upstream bioprocessing applications including gene therapy, pluripotent stem cell (PSC) expansion, organoid formation, HEK-based recombinant proteins and HEK-based vaccine production.

“Scalable, sustainable and single use, Cellevat3d^® nanofiber microcarriers closely mimic the human extracellular environment, providing higher cell densities and enhancing yield for viral vector production compared to current standard microcarriers based processes,” says Laura Chirica, PhD CEO, of Cellevate. “Our nanofiber microcarriers effectively address the key challenges of low productivity and high manufacturing costs facing the industry. With this pre-launch of Cellevat3d^® nanofiber microcarriers starter pack, at CPHI Milan, we’re excited to provide early access to a completely new category of cell culture systems currently unavailable on the market. Cellevat3d^® nanofiber-based cell culture systems truly have the potential to transform biomanufacturing for advanced therapies and take a significant step toward making these therapies more accessible to patients.”

Cellevat3d^® nanofiber microcarriers will be available for pre-order at CPHI Milan from October 8-10, 2024. Book a meeting with Laura Chirica, CEO, Cellevate and Bettina Berendsen, Strategic Advisor and Board Observer, Cellevate to learn more.

The official commercial product launch will follow at BIO-Europe in Stockholm, Sweden, from November 4-6, 2024.

For more information about our innovative Cellevat3d^® nanofiber microcarriers, to place a pre-order or to connect with Cellevate representatives, please visit Cellevate’s updated website.

For more information, please contact:

Laura Chirica, PhD

CEO Cellevate

Email: laura.chirica@cellevate.com

About Cellevate

Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d^® is a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of nanofiber microcarriers – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to an improved biomanufacturing productivity and process economy. Cellevat3d^® microcarriers products are designed as an integrated part of upstream bioprocess solutions, from laboratory to large-scale batch production. Cellevat3d^® nanofiber microcarriers have a commercial launch and sales start in November 2024.  
 

For more information, please visit www.cellevate.com.